GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展  

The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver dis-ease

作　　者：林楚曼 林伟浩 周蕊 杨力[3] Lin Chuman;Lin Weihao;Zhou Rui;Yang Li(Second College of Clinical Medicine, Southern Medical University, Guangzhou 510515, China)

机构地区：[1]南方医科大学第二临床医学院,广州510515 [2]南方医科大基础医学院病理学系,广州510515 [3]南方医科大学珠江医院内分泌代谢科,广州510282

出　　处：《国际内分泌代谢杂志》2018年第3期179-182,共4页International Journal of Endocrinology and Metabolism

基　　金：国家自然科学基金（81270966）;广东省自然科学基金（2014A030310472）;南方医科大学2017年校级大学生创新训练计划项目（201712121342）

摘　　要：既往研究表明,胰高血糖素样肽-1（GLP-1）可改善肝脏脂肪变性,特别是在2型糖尿病患者中.研究GLP-1是否作用于肝细胞并影响非酒精性脂肪性肝病（NAFLD）的进展已成为防治NAFLD的研究热点.近年的研究发现,人肝细胞上有GLP-1受体（GLP-1R）的表达,提示GLP-1可直接作用于GLP-1R,并通过cAMP-蛋白激酶A-AMP活化蛋白激酶/沉默信息调节因子1、胰岛素受体底物1-磷酸肌醇依赖性酶1-蛋白激酶C/蛋白激酶B、Janus激酶-信号转导与转录激活因子、内质网转膜蛋白激酶1 α-c-Jun氨基末端激酶等信号通路调节脂代谢相关基因的表达,改善肝脏脂肪代谢.Previous studies have shown that glucagon-like peptide-1 （GLP-1） can improve hepatic steatosis,especially in patients with type 2 diabetes.Therefore,the study of whether GLP-1 acts on hepatocytes and affects the progress of non-alcoholic fatty liver disease（NAFLD） has become a hotspot in the prevention and treatment of NAFLD.Recent studies have shown that GLP-1 receptor （GLP-1R） was expressed on human hepatocytes,suggesting that GLP-1 could act directly on GLP-1R.Besides,GLP-1 could regulate lipid metabolism-related genes via cAMP-protein kinase A-adenosine 5＇-monophosphate-activated protein kinase/Sirtuin 1,insulin receptor substrate 1-phosphoinositide-dependent protein kinase-l-protein kinase C/protein kinase B,Janus kinase-signal transduction and activator of transcription,inositol-requiring enzyme 1-c-Jun N-terminal kinase signal pathway to improve lipid metabolism of the liver.

关 键 词：胰高血糖素样肽-1 非酒精性脂肪性肝病 信号通路 

分 类 号：R575.5[医药卫生—消化系统]